Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?

Future Oncology

Volumn 7, Issue 3, 2011, Pages 381-383

  Bouganim, Nathaniel ^a   Clemons, Mark J ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

bone metastases; bone targeted agents; denosumab

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BOSUTINIB; CLODRONIC ACID; DENOSUMAB; PAMIDRONIC ACID; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SARACATINIB; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; CANCER PATIENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG SAFETY; HUMAN; HYPOCALCEMIA; NEPHROTOXICITY; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE;

EID: 79953131640     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.192     Document Type: Article

References (14)

1. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
2. Clemons M, Dranitsaris G, Ooi W, Cole DE: A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res. Treat. 108, 79-85 (2008). (Pubitemid 351623243)
3. Plunkett TA, Rubens RD: Bisphosphonate therapy for patients with breast carcinoma. Cancer 97, 854-858 (2003).
4. Coleman RE, Rubens RD: Bone metastases and breast cancer. Cancer Treat. Rev. 12, 251-270 (1985). (Pubitemid 16119038)
5. Coleman RE: Therapeutic use of bisphosphonates in oncology. BMJ 309, 1233 (1994).
6. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br. J. Cancer 55, 61-66 (1987). (Pubitemid 17234155)
7. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J. Clin. Oncol. 24, 4895-4900 (2006). (Pubitemid 46630917)
8. Lowik CW, Boonekamp PM, van de Pluym G, et al. Bisphosphonates can reduce osteoclastic bone resorption by two different mechanisms. Adv. Exp. Med. Biol. 208, 275-281 (1986).
9. Hughes DE, MacDonald BR, Russell RG, Gowen M: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 83, 1930-1935 (1989). (Pubitemid 19148862)
10. Aapro M, Saad F, Costa L: Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist 15, 1147-1158 (2010).
11. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. 21, 4042-4057 (2003). (Pubitemid 46606220)
12. Reddy-K, Nadler E, Jain VK: Denosumab (AMG 162), a fully human monoclonal antibody against RANK ligand activity. Support. Cancer Ther. 3, 14-15 (2005).
13. Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27, 1564-1571 (2009).
14. A Multicentre Study Assessing 12-Weekly Intravenous Bisphosphonate Therapy in Women with Low Risk Bone Metastases from Breast Cancer Using Bone Resorption Markers www.canadiancancertrials.ca/trial/default. aspx?trialid=oct1213&lang=en